



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_JAMPS_22866
Title of the Manuscript:	CYSTEINE PROTEASE INHIBITORS FROM CALOTROPIS PROCERA WITH ANTIPLASMODIAL POTENTIAL IN MICE
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	Ethical Issue-Yes. Any ethical approval sought for animal use in this experiments.	Experiments were conducted in strict compliance with internationally accepted principles for laboratory animal use and care as contained in the Canadian Council on Animal Care Guidelines and Protocol Review (CC,1997).
<u>Minor</u> REVISION comments	<u>General comments</u> The researchers examined of the cystein protease inhibitors extracts of the <i>Calotropis procera</i> for anti-malaria activities. This is an important research in light of emerging antimalarial drug resistance. The paper is well written except for few minor corrections as outlined below. <u>Specific comments</u> Title Ok and informative Abstract Sufficient information Line 16 the word <i>graded</i> could be replaced with <i>incremental</i> doses Introduction Adequate background information. Materials & Methods Generally well described. <u>Under protease inhibitor assay</u> Line 116-117: the authors could consider the name of the instrument used for reading absorbance and how	Thanks Has been change to increamental Spectrophotometer Model : SB038 Was calculated as $A_c - A_i / A_c \times 100$ A_c=Absorbance without inhibitor A_i= Absorbance with inhibitor Carried by two different individuals thirty Different letters within the same parts of plant indicate significant different Values with different superscript letters



SDI Review Form 1.6

	percentage inhibitory activity was calculated. <u>Inoculation of mice and parasite count</u> Line 141: parasites counted twice – was it done by the same person? <u>In vivo antiplasmodial test of crude extracts</u> Line 158: change <i>thiry</i> to <i>thirty</i> Results Figure 1 is labelled with a, b, c with not identifiers. The authors may consider what they represent Table 2: Line 231-232 need to provide clear information on the significant level – the statistically significance is not too clear meaning between which parameters? Figure 5 seems the most important graph with only positive control showing any substantial and significant inhibition of parasitaemia. Others show some initial decline in parasitaemia and rise again after day 10 almost similar to negative control. Discussion Generally fine but it would be better if authors could focus little bit more on Figure 5 why there is post-treatment rise in parasitaemia compared to positive control. Conclusion Generally fine but should also take into account Figure 5 post-treatment rise in parasitaemia	within the same vertical column are significantly different ($P < 0.05$). Each vertical column represent different parameters. Although there rise in parasitemia in the test animals post treatment, they survival longer than negative control group Posttreatment rise could be attributed to the stability of the inhibitor or crude extract is inhibiting Cysteine protease secreted by mature parasite (trophozoite, schizont and merozoite), but had no effect on the ring stages of the parasite. The ring stage is known to produce little or none Cysteine protease enzyme and might be escaping the effect of inhibitor
Optional/General comments		